UNSPSC 51332862: Perphenazine decanoate

This classification denotes an antipsychotic agent C31H44ClN3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RHE0987NHE, chemically known as decanoic acid, 2-(4-(3-(2-chloro-10h-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester, but more generally known as perphenazine decanoate, which bears US NIH Compound Identifier 62873. European Medicines Agency schedules Perphenazine decanoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03716MIG.

Most nations, for tariff and trade purposes, schedule perphenazine decanoate under HS 29343090 and SITC 51578. As of Q4 2014, PERPHENAZINE DECANOATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)CL.

UNSPSC 51332862 Perphenazine decanoate is a Commodity code that captures pharmaceutical products, though the recent state and local activity posted under this code does not reflect procurement of perphenazine decanoate itself. Instead, Seminole County, Florida has used this code to solicit naloxone and safe drug deactivation systems, indicating a mismatch between the code's nominal scope and what is actually being bought. State and local issuing bodies posting under this code appear limited in number based on available recent opportunities; the single posted solicitation came from a county health department supporting community health and emergency response initiatives.

Seminole County, Florida is the only jurisdiction with documented recent activity. Seminole County posted IFB 60459723LAS on June 30, 2026, closing July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract runs two years with a one-year renewal option and requires vendors to meet E-Verify compliance, drug-free workplace certification, and insurance coverage including workers' compensation and commercial general liability. The code shows minimal recent activity and little evidence of the pharmaceutical product indicated by its name in current state and local procurement.